Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit/ hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 18, Issue 1, 2008, Pages 1-10

  Cox, Daniel J ^a,b   Moore, Melissa ^a   Burket, Roger ^a   Merkel, R Lawrence ^a   Mikami, Amori Yee ^a   Kovatchev, Boris ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; LONG ACTING DRUG; METHYLPHENIDATE; PEMOLINE MAGNESIUM; PLACEBO; SHORT ACTING DRUG; SODIUM CHLORIDE;

ADOLESCENT; ADULT; ANALYTICAL ERROR; ARTICLE; ATTENTION DEFICIT DISORDER; CAR DRIVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; URINARY HESITANCY; VIRTUAL REALITY;

ADOLESCENT; ADULT; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTOMOBILE DRIVING; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; HUMANS; MALE; METHYLPHENIDATE; TIME FACTORS;

EID: 39749098369     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0141     Document Type: Article

References (39)

1. th edition (DSM-IV). Washington (DC), American Psychiatric Association, 1994.
2. Arnsten AFT, Castellanos FX: Neurobiology of attention regulation and its disorders. In: Pediatric Psychopharmacology. Edited by Martin A, Scahill L, Charney DS, Leckman JF. New York, Oxford University Press, 2003, pp 99-109.
3. Barkley RA, Murphy KR, Kwasnik D: Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 98:1089-1095, 1996.
4. Barkley RA: Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27:233-260, 2004.
5. Barkley RA: Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York, Guilford Press, 2005.
6. Biederman J: Practical considerations in stimulant drug selection for the attention-deficit/hyperactivity disorder patient - efficacy, potency and titration. Today's Therapeutic Trends 20:311-328, 2002.
7. Carlson G, Kelly K: Stimulant rebound: How common is it and what does it mean. J Child Adolesc Psychopharmacol 13:137-142, 2003.
8. Cox DJ, Gonder-Frederick L, Clarke W: Driving decrements in type I diabetes during moderate hypoglycemia. Diabetes 42:239-243, 1993.
9. Cox DJ, Quillian WC, Gressard CF, Westerman P, Gonder-Frederick LA, Canterbury R: The effects of blood alcohol levels on driving variables in a high risk population: Objective and subjective measures. J Alcohol Drug Educ 40:84-98, 1995.
10. Cox DJ, Quillian WC, Thorndike FP, Kovatchev BP, Hanna G: Evaluating driving performance of outpatients with Alzheimer disease. J Am Board Fam Pract 11:264-271, 1998.
11. Cox DJ, Taylor P, Kovatchev B: Driving simulation performance predicts future accidents among older drivers. J Am Geriatr Soc 47:381-382, 1999.
12. Cox DJ, Gonder-Frederick LA, Kovatchev BP, Julian DM, Clarke WL: Progressive hypoglycemia's impact on driving simulation performance: Occurrence, awareness and correction. Diabetes Care 23:163-170, 2000a.
13. Cox DJ, Merkel RL, Kovatchev B, Seward R: Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: A preliminary double-blind placebo controlled trial. J Nerv Ment Dis 188:230-234, 2000b.
14. Cox DJ, Broshek DK, Kiernan BP, Kovatchev BP, Guerrier J, Giulano A, George C: Specific driving impairments with progressive age. Advances in Medical Psychotherapy and Psychodiagnosis 11:107-122, 2002a.
15. Cox DJ, Gonder-Frederick LA, Kovatchev BP, Clarke WL: The metabolic demands of driving for drivers with type 1 diabetes mellitus. Diabetes Metab Res Rev 18:381-385, 2002b.
16. Cox DJ, Kovatchev BP, Gonder-Frederick LA, Clarke WL: Physiological and performance differences between drivers with type 1 diabetes mellitus (T1DM) with and without a recent history of driving mishaps: An exploratory study. Canad J Diabetes 27:23-29, 2003.
17. Cox DJ, Humphrey JW, Merkel RL, Penberthy JK, Kovatchev BP: OROS methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract 17:235-239, 2004a.
18. Cox DJ, Merkel RL, Penberthy JK, Kovatchev B, Hankin CS: Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: A pilot study. J Am Acad Child Adolesc Psychiatry 43:269-275, 2004b.
19. Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B: Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 118:e704-e710 Sept 2006.
20. Dingus TA, Klauer SG, Neale VL, Petersen A, Lee SE, Sudweeks J, Perez MA, Hankey J, Ramsey D, Gupta S, Bucher C, Doerzaph ZR, Jermeland J: The 100-car naturalistic driving study: Phase II - results of the 100-car field experiment. (Interim Project Report for DTNH22-00-C-07007, Task Order 6, Report No. DOT HS 810 593). Washington (DC), National Highway Traffic Safety Administration (2006).
21. DuPaul G, Power T, Anastopolous A, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, Guilford Publications, 1998.
22. Garland EJ: Pharmacotherapy of adolescent attention deficit hyperactivity disorder: Challenges, choices, and caveats. J Psychopharmacol 12:385-395, 1998.
23. Gracevich S, Read SC, Sea D, Mays DA, Tulloch SJ: Safety and efficacy of MAS XR in adolescents with ADHD. 51st annual meeting of the American Academy of Child and Adolescent Psychiatry, 2004 (poster).
24. Johnston C, Pelham W, Hoza J, Sturges J: Psychostimulant rebound in attention deficit disordered boys. J Am Acad Child Adolesc Psychiatry 27:806-810, 1988.
25. McCracken JT, Biederman JL, Greenhill l, Swanson JM, McGough JJ, Spencer TJ, Posner K, Wigal S, Pataki C, Zhang X, Tulloch S. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 42:673-683, 2003.
26. McGough JJ, Biederman J, Greenhill LL, McCracken JT, Spencer TJ, Posner K, Wigal S, Gornbein J, Tulloch S, Swanson JM. Pharmacokinetics of SLI381 (Adderall XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 42:684-691, 2003.
27. Murphy K, Barkley RA: Attention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments. Compr Psychiatry 37:393-401, Nov-Dec 1996.
28. National Highway Traffic Safety Administration. Young Drivers Traffic Safety Facts. 2003.
29. Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M, Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder: The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642-657, 2006.
30. Porrino LJ, Rapoport JL, Behar D, Ismond DR, Bunney WE, Jr: A naturalistic assessment of the motor activity of hyperactive boys. II. Stimulant drug effects. Arch Gen Psychiatry 40:688-693, Jun 1983.
31. Quillian WC, Cox DJ, Gonder-Frederick LA, Driesen NR, Clarke WL: Reliability of driving performance during moderate hypoglycemia in adults with IDDM. Diabetes Care 17:1367-1368, 1994.
32. Quillian WC, Cox DJ, Kovatchev BP, Phillips C: The effects of age and alcohol intoxication on simulated driving performance, awareness and self-restraint. Age 28:59-66, 1999.
33. Rapoport JL, Buschsbaum MS, Zahn TP, Weingartner H, Ludlow C, Mikkelsen EJ: Dextroamphetamine: Cognitive and behavioral effects in normal prepubertal boys. Science 199:560-563, 1978.
34. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): Description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 39:28-38, 2000.
35. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113(3 pt 1):e206-e216, 2004.
36. Valez CN, Johnson J, Cohen P: A longitudinal analysis of selected risk factors for childhood psychopathology. J Am Acad Child Adolesc Psychiatry 28:861-864 1989.
37. Wilens T, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM: A multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160:82-90, 2006.
38. Williams AF: Teenage drivers: Patterns of risk. J Safety Res 34:5-15, 2003.
39. Wolraich ML, Doffing MA: Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 18:243-250, 2004.